Skip to main content

Table 1

From: Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial

n (%) Minimal Disease Activity
  ADA Continuation PBO P-value
  +MTX -MTX +MTX -MTX  
Week 16 28 (37.3) 19 (33.9) NA NA NA
Week 48 19 (76.0) 14 (56.6) 15 (62.5) 13 (68.4) 0.8919
Week 88 26 (83.9) 20 (76.9) 14 (50.0) 13 (65.0) 0.0075
  Minimal Disease Activity with Normal Function
Week 16 21 (28.0) 15 (26.8) NA NA NA
Week 48 17 (68.0) 12 (48.0) 15 (62.5) 13 (68.4) 0.5155
Week 88 24 (77.4) 17 (65.4) 14 (50.0) 11 (55.0) 0.0362